AstraZeneca beats second-quarter profit expectations
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Alico, Inc. to Announce Third Quarter 2025 Financial Results on Tuesday, August 12, 2025
FORT MYERS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Alico, Inc. ('Alico' or the 'Company') (Nasdaq: ALCO) today announced that the Company will release financial results for the third quarter ended June 30, 2025, on Tuesday, August 12, 2025 after market close. The Company will host a conference call to discuss its financial results on Wednesday, August 13, 2025, at 8:30 am Eastern Time. Interested parties may join the conference call by dialing 1-800-267-6316 in the United States and 1-203-518-9783 from outside of the United States. The participant identification to join the conference call is ALICO. A telephone replay will be available on Wednesday, August 13, 2025 approximately three hours after the call concludes, and will be available through Wednesday, August 27, 2025. Listeners in the United States may dial 1-844-512-2921 and international listeners may dial 1-412-317-6671. The passcode for the playback is 11159421. About Alico Alico, Inc. (Nasdaq: ALCO) is a Florida-based agribusiness and land management company with over 125 years of experience. Following its strategic transformation in 2025, Alico operates as a diversified land company with approximately 51,300 acres across 8 Florida counties. The Company focuses on strategic land development opportunities and diversified agricultural operations, leveraging its extensive land portfolio to create long-term shareholder value while maintaining its commitment to responsible land stewardship and conservation. Learn more about Alico at Investor Contact:John MillsICR(646) 277-1254InvestorRelations@ Brad HeineChief Financial Officer(239) 226-2000bheine@ in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Ford reports Q2 earnings beat but takes $800M tariff hit
Ford (F) posted an earnings and revenue beat for the second quarter, reinstated full-year guidance, but upped its full-year tariff exposure after seeing $800 million in tariff costs in Q2 alone. For the year, Ford said it now expects a "net tariff-related headwind of about $2 billion," which reflects a $3 billion gross adverse adjusted EBIT (earnings before interest and taxes) impact, partially offset by $1 billion of mitigation efforts. Ford CFO Sherry House said on a call with reporters that mitigation efforts could include higher pricing for certain vehicles or using "bonded" rail carriers between Canada and Mexico. Ford also issued new guidance, with full-year adjusted EBIT seen at $6.5 billion to $7.5 billion, which the company says now takes into account the $2 billion tariff impact. Ford also said it sees full-year adjusted free cash flow in a range of $3.5 billion to $4.5 billion, with capital expenditures of about $9 billion. Ford shares were volatile in after-hours trading, down over 4% immediately following the news. Prior to withdrawing guidance in February, the company had seen full-year adjusted EBIT guidance $7.0 billion to $8.5 billion. For the quarter, Ford reported revenue of $50.2 billion vs $44.14 billion estimated per Bloomberg consensus, up 5% compared to a year ago. Ford posted adjusted earnings per share (EPS) of $0.37 vs. $0.33 expected, on adjusted EBIT (earnings before interest and taxes) of $2.1 billion vs $1.91 billion estimated. Ford said its adjusted EBIT was impacted by $800 million in net tariff exposure in Q2. Last week Big Three rival GM (GM) reported profit dipped in Q2 as tariffs added $1.1 billion to costs. And Dodge-parent Stellantis (STLA) said on Tuesday that tariffs ate away nearly $350 million in profit in Q2, with the full-year tally expected at $1.73 billion. The impact of tariffs, as well as rising warranty costs for recalls that have plagued Ford vehicles weighed on results. For example, Ford booked a $570 million charge in Q2 related to the recall of 700,000 SUVs due to fire risk. As part of its Ford+ plan, Ford divided its business into three units: Ford Blue for the traditional gas-powered business, Ford Model e for the electric vehicle division, and Ford Pro for its commercial and super duty truck business. Ford reported the following in Q2: Ford Blue: $25.8 billion in revenue, $661 million in EBIT Model e: $2.4 billion in revenue, -$1.329 billion in EBIT Ford Pro: $18.8 billion in revenue, $2.318 billion in EBIT Look for Farley to weigh in on trade deals the Trump team struck with the UK and EU on the earnings call; Farley has said deals like those are unfair given the fact vehicles imported from Canada and Mexico, which use a high-percentage of US-made parts, are tariffed at a much higher 25%. Despite tariffs, Ford saw sales gains in Q2 as the company's employee pricing for all strategy was a huge sales mover. Ford posted Q2 US sales of 612,095 units, a 14% jump compared to a year ago and well ahead of the 1.7% estimated industry sales growth rate. Hybrid (+23%) sales for vehicles like the Maverick, and gas-powered vehicle sales (+15%) like the Bronco SUV drove the sales gains, while EV sales lagged (-31%). Speaking of EVs, commentary from executives on the outlook for business given the loss of consumer EV tax credits will be another item on the agenda. Pras Subramanian is the lead auto reporter for Yahoo Finance. You can follow him on X and on Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase. The company reported earnings per American Depositary Share (EPADS) of 52 cents, surpassing analyst expectations of 47 cents. However, in yen terms, earnings per share (EPS) experienced a 14.1% decline, or a 10% decrease when adjusted for constant currency, reaching 151 yen. Total sales for the quarter amounted to $7.66 billion (1.11 trillion yen), exceeding consensus estimates of $7.53 billion. Despite this positive top-line performance, Takeda faced challenges on the bottom line, with core net profit dropping by 14.4% (or 10.3% at constant currency) to 237 billion key factor behind this decline was the significant erosion of revenue from Vyvanse, its attention-deficit hyperactivity disorder (ADHD) treatment, following the introduction of generic competition. This decline was anticipated by the company and was a major contributor to both the revenue drop and a reduction in core operating profit. View more earnings on TAK U.S. sales of Vyvanse fell 53.8% at constant exchange rates, dropping to 57.9 billion yen. The generics' market entry led to an overall sales decline of 46.9% for the drug during the quarter. On a more positive note, Takeda's portfolio of rare disease treatments showed resilience. Sales of Takhzyro, a treatment for hereditary angioedema, rose by 3.7% to 55.1 billion yen. Immunoglobulin sales also saw growth, increasing 2% at constant currency to 194 billion yen, while Albumin sales surged 16.2%, reaching 32.2 billion yen. In the vaccine segment, Takeda's Qdenga dengue vaccine experienced a 4.8% decline in sales at constant currency, amounting to 8.8 billion yen. However, the oncology division performed solidly, with Adcetris sales climbing 13.2% to 37.2 billion yen, while Fruzaqla, a novel therapy for certain cancers, saw a more modest growth of 8.9%, reaching 12.3 billion yen. Takeda's operating profit for the quarter rose 11% to 184.6 billion yen, while core operating profit dropped 15.8% (down 11.9% on a constant currency basis) to 321.8 billion yen. This decrease was primarily due to lower year-over-year impairment and restructuring expenses. Milano Furuta, Takeda's CFO, commented on the results, noting, 'The impact of Vyvanse generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May.' Outlook Takeda reaffirms its fiscal 2025 guidance, with core revenue of 4.53 trillion yen and core operating profit broadly flat at 1.14 trillion yen, and core earnings of 485 yen. Price Action: TAK stock is trading lower by 4.99% to $13.61 at last check Wednesday. Read Next:Photo by Veroniksha via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
